Insulin receptor signaling characteristics in vivo

被引:23
作者
Hennige, AM [1 ]
Lehmann, R [1 ]
Weigert, C [1 ]
Moeschel, K [1 ]
Schäuble, M [1 ]
Metzinger, E [1 ]
Lammers, R [1 ]
Häring, HU [1 ]
机构
[1] Univ Tubingen, Dept Internal Med 4, D-72076 Tubingen, Germany
关键词
D O I
10.2337/diabetes.54.2.361
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In recent years, recombinant DNA technology has been used to design insulin molecules that overcome the limitations of regular insulin in mealtime supplementation. However, safety issues have been raised with these alternatives, as the alteration of the three-dimensional structure may alter the interaction with the insulin and/or IGF-I receptors and therefore lead to the activation of alternate metabolic as well as mitogenic signaling pathways. It is therefore essential to carefully study acute and long-term effects in a preclinical state, as insulin therapy is meant to be a lifelong treatment. In this study, we determined in vivo the insulin receptor signaling characteristics activated by insulin glulisine (LySB3, GIUB29) at the level of insulin receptor phosphorylation, insulin receptor substrate phosphorylation, and downstream signaling elements such as phosphatidylinositol (PI)3-kinase, AKT, and mitogenactivated protein kinase. C57B/6 mice were injected with insulin glulisine or regular insulin and Western blot analysis was performed for liver and muscle tissue. The extent and time course of insulin receptor phosphorylation and activation of downstream signaling elements after insulin glulisine treatment was similar to that of human regular insulin in vivo. Moreover, insulin signaling in hypothalamic tissue determined by PI 3-kinase activity was comparable. Therefore, insulin glulisine may be a useful tool for diabetes treatment.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 17 条
[1]   Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus [J].
Anderson, JH ;
Brunelle, RL ;
Keohane, P ;
Koivisto, VA ;
Trautmann, ME ;
Vignati, L ;
DiMarchi, R .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (11) :1249-1255
[2]   Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment [J].
Anderson, JH ;
Brunelle, RL ;
Koivisto, VA ;
Pfutzner, A ;
Trautmann, ME ;
Vignati, L ;
DiMarchi, R ;
Bowen, KM ;
Cameron, DP ;
Nankervis, AJ ;
Roberts, AP ;
Zimmet, P ;
Borkenstein, MH ;
Schernthaner, G ;
Waldhausl, WK ;
DeLeeuw, IH ;
Fery, F ;
Scheen, A ;
Somers, G ;
Fettes, IM ;
Tildesley, HD ;
Toth, EL ;
Viikari, J ;
Altman, JJ ;
Bougneres, PF ;
Drouin, P ;
Fossati, P ;
Guillausseau, PJ ;
Marechaud, E ;
Riou, JP ;
Selam, JL ;
Vialettes, PB ;
Beyer, J ;
Federlin, K ;
Fussganger, RD ;
Gries, FA ;
Jastram, HU ;
Koop, I ;
Landgraf, R ;
Rosak, C ;
Schatz, H ;
SchulzeSchleppinghoff, B ;
Seif, FJ ;
Stoeckmann, F ;
Karasik, A ;
Weitzman, S ;
Andreani, D ;
Bompiani, G ;
Crepaldi, G ;
Giorgino, R .
DIABETES, 1997, 46 (02) :265-270
[3]   PKB binding proteins: Getting in on the akt [J].
Brazil, DP ;
Park, J ;
Hemmings, BA .
CELL, 2002, 111 (03) :293-303
[4]   IRS-2 pathways integrate female reproduction and energy homeostasis [J].
Burks, DJ ;
de Mora, JF ;
Schubert, M ;
Withers, DJ ;
Myers, MG ;
Towery, HH ;
Altamuro, SL ;
Flint, CL ;
White, MF .
NATURE, 2000, 407 (6802) :377-382
[5]   Insulin glargine: long-acting basal insulin analog for improved metabolic control [J].
Gerich, JE .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (01) :31-37
[6]   Novel insulins: Expanding options in diabetes management [J].
Gerich, JE .
AMERICAN JOURNAL OF MEDICINE, 2002, 113 (04) :308-316
[7]  
Hennige AM, 1999, DIABETOLOGIA, V42, pA178
[8]   Upregulation of insulin receptor substrate-2 in pancreatic β cells prevents diabetes [J].
Hennige, AM ;
Burks, DJ ;
Ozcan, U ;
Kulkarni, RN ;
Ye, J ;
Park, SM ;
Schubert, M ;
Fisher, TL ;
Dow, MA ;
Leshan, R ;
Zakaria, M ;
Mossa-Basha, M ;
White, MF .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (10) :1521-1532
[9]   Leptin activates PI-3 kinase in C2C12 myotubes via janus kinase-2 (JAK-2) and insulin receptor substrate-2 (IRS-2) dependent pathways [J].
Kellerer, M ;
Koch, M ;
Metzinger, E ;
Mushack, J ;
Capp, E ;
Haring, HU .
DIABETOLOGIA, 1997, 40 (11) :1358-1362
[10]   Insulin analogues:: impact of cell model characteristics on results and conclusions regarding mitogenic properties [J].
Kellerer, M ;
Häring, HU .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2001, 109 (01) :63-64